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Abstract
Background: Patients with osteoarthritis (OA) take a variety of health supplements in an attempt to reduce pain
and improve function. The aim of this study was to determine the efficacy of methylsulfonylmethane (MSM) in
treating patients with knee OA.
Methods: This study was a prospective, randomized, double-blind, controlled clinical trial. Forty nine men and
women 45-90 (mean 68 ± SD 7.3) years of age with knee OA according to the American College of Rheumatology
clinical criteria for OA of the knee and with radiographic confirmed knee OA were enrolled in the study and
randomly assigned into 2 groups: One received MSM in doses of 1.125 grams 3 times daily for 12 weeks and the
other received a placebo in the same dosing frequency. The primary outcomes were the WOMAC Osteoarthritis
Index for pain, stiffness and physical function, the Aggregated Locomotor Function (ALF) test that evaluates each
patient’s physical function, the SF-36 quality of life health survey and the visual-analogue-scale (VAS) for pain. The
secondary outcomes were Knee Society Clinical Rating System for Knee Score (KSKS) and Function Score (KSFS).
Patients were assessed at baseline, 6 weeks and 12 weeks. All continuous variables were tested by the
Kolmogorov-Smirnov test for Normal distribution. Changes within the groups and differences between the groups
were calculated by repeated measures of analysis (ANOVA) with one nested variable.
Results: There were significant differences between treatment groups over time in WOMAC physical function (14.6
mm [CI: 4.3, 25.0]; p = 0.04) and in WOMAC total score (15.0 mm [CI: 5.1, 24.9]; p = 0.03). Treatment groups did not differ
significantly in WOMAC pain (12.4 mm [CI: 0.0, 24.8]); p = 0.08) or WOMAC stiffness (27.2 mm [CI: 8.2, 46.2]; p = 0.08).
There was a non-significant difference in SF-36 total score between treatment groups (11.6 [CI: 1.0, 22.1]; p = 0.54). A
significant difference was found between groups in VAS for pain (0.7 s [CI: -0.9, 2.4]; p = 0.05). Secondary outcomes
showed non-significant differences between the two groups.
Conclusions: Patients with OA of the knee taking MSM for 12 weeks showed an improvement in pain and physical
function. These improvements, however, are small and it is yet to be determined if they are of clinical significance.
Trial Registration: ClinicalTrials.gov: NCT01188213
Background
Osteoarthritis (OA) is the primary cause of disability in the
elderly, affecting nearly 27 million individuals in the Uni-
ted States alone [1]. Knee OA is the most common type of
OA, with an estimated 12.1% of adults in the United States
suffering from pain and functional limitations [2]. Given
the association of OA with old age, these figures can be
expected to rise significantly with the aging of the baby
boomer population in the United States and with the
increased longevity in the world’s population. Currently,
there is no cure for OA and treatment is focused on redu-
cing pain and improving function [3].
Many drugs have arisen in an attempt to alleviate pain
and disability, including acetaminophen, nonsteroidal anti-
inflammatory drugs (NSAIDs) such as cyclooxygenase-2
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have also turned to surgical interventions and complemen-
tary and alternative medicine (CAM) as they have some
ameliorating effects as well [3,6]. Due to recent safety con-
cerns regarding COX-2 selective drugs, patients have
turned to dietary supplements sold over-the-counter
(OTC) that claim to be safer in the long-term treatment of
OA. These include glucosamine and chondroitin sulfate,
both of which have been examined in previous studies
[7-9]. Methylsulfonylmethane (MSM) is another OTC
drug that is often sold in combination with glucosamine
and chondroitin sulfate. MSM can be bought at health
food stores and on the internet in products such as creams
and capsules.
MSM is an organosulfur molecule that can be synthe-
sized commercially from dimethylsulfoxide (DMSO).
MSM is even naturally present in the human body as it is
metabolized from ingested DMSO. It can be found in cer-
ebrospinal fluid and plasma at 0-25 μmol/l concentrations
[10,11]. Many properties have been attributed to MSM,
some of which include chemopreventive properties, anti-
inflammatory activities, anti-atherosclerotic action, prosta-
cyclin (PGI2) synthesis inhibition and free radical scaven-
ging activity [12-14]. Nevertheless, conclusive data on the
biochemical effects and mechanism of action of MSM is
minimal. Even less is known about how these effects may
benefit patients with OA of the knee.
A study by Usha and Naidu found that patients with
knee OA treated with MSM showed a 33% pain reduc-
tion on the visual-analogue-scale (VAS) for pain (p <
0.001) [15]. A study by Kim et al. found that knee OA
patients treated with MSM showed a significant decrease
in the Western Ontario and McMaster University
Osteoarthritis Index visual analogue scale (WOMAC) in
pain and physical function impairment (p = 0.041 and
0.045, respectively) [16]. In a meta-analysis by Brien et
al., the efficacy of MSM and DMSO was evaluated in
reducing pain associated with knee OA [17]. Overall a
significant but non-clinically significant reduction of pain
on visual analogue scale of 6.34 mm (SE = 3.49 [CI: -0.49,
13.17]) was found in favor of MSM/DMSO, with an over-
all effect size of 1.82. This effect size was calculated by
dividing the difference between the changes seen in each
treatment group over time by the estimated standard
error.
A review article by Brien et al. [18] discussed the many
shortcomings of studies on DMSO and MSM. In terms of
d o s a g e ,t h eM S Md o s a g eu s e db yU s h a( 5 0 0m g3t i m e s
daily for 12 weeks) was lower than the recommended
dosage of MSM for clinical practice. The dosage used by
Kim et al. (3 g twice a day for 12 weeks) was in the upper
range of the appropriate therapeutic MSM dosage. Both
studies had a clinically relevant time period. In addition,
the study by Usha failed to report all the primary outcomes
and the study by Kim et al. showed non-clinically signifi-
cant results. In terms of the safety of MSM, the study by
Usha reported minor gastrointestinal (GI) side effects in
5% of patients but did not state in which treatment group.
The study by Kim et al. found GI problems, headaches,
insomnia, fatigue and/or concentration problems in 57% of
patients in the MSM group [18]. Other literature on MSM
have also reported unproven side effects of increased blood
pressure, increased effectiveness of anticoagulants and ele-
vated liver function tests [19]. Based on these findings,
Brien et al. suggested that future studies on MSM are
needed to identify the optimum dosage and safety of
MSM. They believe that future large-scale, long-term
phase II studies are needed [18].
The purpose of this study was to evaluate the efficacy
and safety of MSM in treating patients with OA of the
knee at a dosage of 3.375 g/d for 12 weeks. This dosage
falls between those used by the studies of Usha and Kim
et al. Other measurement outcomes were also added to
the study, such as real-time physical function measure-
ments, in order to gain a greater understanding of any
functional changes in the patient population.
Methods
Patient population
All patients gave written informed consent prior to enter-
ing the study. The protocol was approved by the Institu-
tional Helsinki Committee Registry of Assaf Harofeh
Medical Center in May 2005 (Helsinki Registration Num-
ber 13/05). The study is registered in the NIH clinical trial
registry, protocol No. NCT01188213. The study was con-
ducted at the Department of Orthopedics of Assaf Haro-
feh Medical Center in Zerifin, Israel, from September 2005
to February 2006. Eligibility was defined as symptomatic
knee OA for at least 6 months according to the clinical
criteria of the American College of Rheumatology (ACR)
[20] and radiographic confirmed knee OA according to
the Kellgren & Lawrence scale [21]. Exclusion criteria
included acute septic arthritis; inflammatory arthritis; any
other type of arthritis; history of knee buckling or recent
knee injury; lack of physical or mental ability to perform
or comply with the treatment procedure; diabetes mellitus;
fibromyalgia or other chronic pain syndromes; concurrent
anti-coagulant/anti-platelet drugs; arthroscopy or intra-
articular injections in the previous 3 months. Patients
using other arthritis therapies (CAM, etc.) and patients
using NSAIDs were required to undergo a 10-day washout
period before enrollment.
Enrollment
Patients were recruited from the Assaf Harofeh Medical
Center outpatient clinic. Over several months at the clinic
hundreds of patients came in to be examined for regular
medical problems. 60 patients who were examined by
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study. These patients were assessed by the orthopedists on
staff for eligibility to the study according to the inclusion
and exclusion criteria. 50 patients were determined to
meet the study criteria and were immediately enrolled into
the study on that day. The 50 qualified patients were
assigned to an MSM (n = 25) or placebo (n = 25) group
(Figure 1).
The study was a 12-week randomized, double-blind, pla-
cebo-controlled trial using random numbers (Figure 1).
Random numbers were assigned as follows: Once the
orthopedist on staff determined a patient’s eligibility to the

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♦Declined to participate (n=0) 
♦Other reasons (n=0) 
Lost to follow-up for WOMAC (forgot to 
complete questionnaire) (n=1) 
Discontinued intervention (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to MSM (n=25) 
♦Received allocated intervention (n=25)
♦Did not receive allocated intervention (n=0)
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to Placebo (n=25) 
♦Received allocated intervention (n=25)
♦Did not receive allocated intervention (n=0)
Lost to follow-up (snakebite) (n=1) 
Discontinued intervention (n=0) 


12		
		
Randomized (n=50) 

	
Included in ITT analysis (n=25) 
♦Excluded from analysis (n=0)
Included in ITT analysis (n=25) 
♦Excluded from analysis (n=0)


 
Flow chart of assessment, enrollment and follow-up 
Figure 1 Study flow chart. Flow chart of assessment, enrollment and follow-up
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tion of the study. The numbers were assigned according to
the order in which they were enrolled in the study (i.e., the
first patient to consent to the study and meet the study
criteria was assigned the number 1). After being assigned
a number and after being scored in all the study measure-
ments for baseline data, the patient was then given a bottle
of pills. All even numbers received bottles from one box
and all odd numbers received bottles from the other box.
The boxes were two large white cardboard boxes filled
with 40 plastic bottles containing the appropriate 12-week
dosage of either MSM or placebo. They were prepared by
individuals who knew nothing about the study. The dosage
bottles were labeled only with a serial number. The serial
numbers were examined at the end of the 12 weeks and
showed that the even numbered patients had received
MSM and the odd numbered patients had received the
placebo.
Dosage
A dosage of 1.125 g 3x/day was chosen for the study.
Purified MSM (MSM Relief, Taam Teva Altman, Israel)
in 1.125 g tablets was used. Study participants were
instructed to take the doses with food and to avoid tak-
ing them before bed. The placebo was comparable in all
characteristics to the MSM.
Patient evaluation
The patients were scored at baseline, 6 weeks and 12
weeks at the Assaf Harofeh Medical Center outpatient
clinic. In patients suffering from bilateral knee OA, the
more symptomatic knee during the initial examination
was chosen for efficacy evaluation. The primary out-
comes of the study were the WOMAC questionnaire
[22,23], the Aggregated Locomotor Function (ALF) score
[24], the SF-36 health survey score [25] and the VAS for
pain [26]. The WOMAC includes pain, stiffness, physical
function and aggregated total symptoms subscales that
were scored from 0 mm to 100 mm (0 = no pain, 100 =
worst pain). A Hebrew version of the WOMAC was used
in the study, which was shown by Wigler et al. to be a
reliable and valid instrument for evaluating the severity
of knee OA in Israeli patients [27]. The ALF score is a
sum of the mean timed scores (seconds) on three loco-
motor functions: time taken to walk 8 meters, time taken
to ascend and descend 7 stairs, and time taken to transfer
from a sitting to standing position. The SF-36 is a health
survey on pain and quality of life that is scored from 0-
100 (0 = worst pain and quality of life, 100 = no pain and
the best quality of life). The VAS is a subjective measure-
ment that the patient reports on a 10 cm horizontal line,
where 0 indicates no pain and 10 the worst pain. The
VAS is particularly useful in assessing changes in pain for
individuals receiving therapy [28].
Secondary outcomes were the Knee Society Clinical
Rating System [29,30] scores. This system is split into
two parts: the Knee Society Knee Score (KSKS) and the
Knee Society Function Score (KSFS). These are both
graded from 0-100 points, with 100 being the best possi-
ble quality of the knee joint or the best functional use of
the knee joint, respectively.
At each follow-up patient compliance and safety was
evaluated. For compliance, patients were asked directly
if they were taking their medication as they were
instructed. The number of pills left in the pill bottle was
also counted at each follow-up. For safety, patients were
asked if there were any side effects or symptoms they
were experiencing that they hadn’te x p e r i e n c e db e f o r e
the study. Each patient ended the study on the day he
o rs h ec a m ei nf o rt h ef i n a lf o l l o w - u p .T h ee n t i r es t u d y
e n d e do nt h ed a yt h a tl a s tp a t i e n tc a m ei nf o rt h ef i n a l
follow-up in February 2006. There were no differences
in follow-up time between patients.
Statistical analysis
The criteria for a clinical response to a treatment have
been defined by the Outcome Measures in Rheumatol-
ogy Clinical Trials (OMERACT) and Osteoarthritis
Research Society International (OARSI). These defini-
tions are specific to visual-analogue-scales graded from
0-100 mm that can stand-alone or as part of a larger
scale such as the WOMAC questionnaire. A clinical
response is considered either an improvement in pain or
in function of at least 50% with a decrease of 20 mm on
the VAS for pain or function, or an improvement in
both pain and function of at least 20% with a decrease
of 10 mm on the visual-analogue-scales.
We examined the randomized assignment process by
testing the hypothesis that the two groups were compar-
able in baseline scores of all outcomes as well as age and
BMI. Chi-Square tests were used for comparing gender
and BMI between the two groups. Intention to treat (ITT)
analysis was carried out in order to include all the rando-
mized patients within the analysis. In the case of any study
drop-outs, the same values that were measured in the fol-
low-up before drop-out were used for the follow-ups after
drop-out.
All continuous variables were tested by the Kolmo-
gorov-Smirnov test for Normal distribution. Changes
within the groups and differences between the groups in
primary and secondary outcomes were calculated by
repeated measures analysis (ANOVA) with one nested
variable. The one nested variable was made up of the two
study groups: MSM and placebo. Additional nested vari-
ables were added to the analysis in order to adjust for
any baseline differences in the distribution of certain
variables (e.g. gender) between the groups. Results before
and after adjustment are presented. The results from the
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ences between groups.
We examined three tests of significance: difference in
changes over time between groups, total changes over
time for both groups and difference between groups in
general. These three tests are appropriate for examining
our hypothesis, which assumes: a) clinically significant
improvement in scale for the active group; b) no clini-
cally significant improvement in scale for the control
group; c) no advantage in scale for the active group
compared to the control group at baseline. The repeated
measures analysis takes into account all three tests and
a multiple comparisons correction. The analysis was
performed by an external statistician using SPSS soft-
ware version 14.0 (SPSS, Chicago).
Results
There were significant differences between the groups at
baseline in gender, BMI and ALF scores (Table 1). The
analyses performed on the data and the results found
were adjusted to account for these differences. Tables 2
and 3 present the unadjusted and adjusted results both
after 6 weeks and at the 12-week endpoint. On the final
follow-up, 1 patient from the placebo group dropped
out due to a snakebite and 1 patient from the MSM
group forgot to complete the WOMAC questionnaire
(Figure 1). These patients were still included within the
ITT analysis. All patients in each group reported full
compliance with the treatment protocol when ques-
tioned at each follow-up. In addition, pill bottles had
the appropriate number of pills at each follow-up. None
of the patients reported any side effects or symptoms
that they hadn’t experienced before the study.
For the primary outcomes there was a significant dif-
ference between the changes in the WOMAC physical
function and aggregated total symptoms in the experi-
mental group compared to the control group after 12
weeks (p-value = 0.04 and 0.03, respectively). From
baseline to the 12-week endpoint, physical function
decreased by 17% (7.7 mm [CI: -0.3, 15.8]) in the MSM
group and increased by 15% (6.9 mm [CI: 0.1, 13.9]) in
the placebo group, corresponding to a difference of 14.6
mm [CI: 4.3, 25.0] between groups (p = 0.04). Total
symptoms decreased by 20% (8.4 mm [CI: 1.1, 15.8]) in
the MSM group and increased by 14% (6.6 mm [CI: 0.5,
13.5]) in the placebo group, corresponding to a differ-
ence of 15.0 mm [CI: 5.1, 24.9] between groups (p =
0.03). No significant difference was found between treat-
ment groups over time in the WOMAC pain or stiffness
subscales. Pain decreased by 21% (9.0 mm [CI: -0.9,
18.9]) in the MSM group and increased by 9% (3.5 mm
[CI: -4.5, 11.5]) in the placebo group. The difference in
pain improvement was 12.4 mm [CI: 0.0, 24.8] between
the groups (p = 0.08). Stiffness decreased by 26% (11.7
mm [CI: -1.0, 24.3]) in the MSM group and increased
by 37% (15.5 mm [CI: 0.7, 30.3]) in the placebo group,
corresponding to a difference of 27.2 mm [CI: 8.2, 46.2]
between groups (p = 0.08).
There was a non-significant improvement in ALF and
SF-36 scores. In ALF the MSM group showed a decrease
of 15% (6.8 seconds [CI: 2.5, 11.0]) in function tests. On
the other hand there was only an increase of 1% (0.8 sec-
onds [CI: -1.2, 2.8]) in the placebo group, corresponding
to a difference of 7.6 seconds [CI: 2.9, 12.2] between
groups (p = 0.09). In SF-36 the MSM group showed an
improvement of 15% (8.1 [CI: -0.8, 17.1]) in pain and
quality of life, while the placebo group instead showed a
decrease of 6% (3.4 [CI: -2.6, 9.5]). This corresponded to
a difference of 11.6 [CI: 1.0, 22.1] between the changes in
each treatment group (p = 0.54).
The MSM group showed a significant reduction in
pain on the VAS. There was a reduction of 6% (0.2 cm
Table 1 Baseline characteristics of the two study groups
Characteristic MSM
(N = 25)
Placebo
(N = 25)
p value*
Kellgren and Lawrence Grade
Grade 1 4 8
Grade 2 7 6
Grade 3 4 6
Grade 4 10 5 0.324
Male gender 4 13 0.007*
Age 67.0 ± 9.8 71.0 ± 8.3 0.203
Body mass index (BMI) 31.4 ± 5.4 28.6 ± 3.09 0.037*
WOMAC (0-100 mm scale)
Pain subscale 42.4 ± 25.7 45.9 ± 27.4 0.641
Stiffness subscale 46.7 ± 24.8 43.0 ± 35.6 0.671
Function subscale 39.9 ± 21.2 47.4 ± 21.9 0.221
Aggregated total score 40.9 ± 20.3 47.0 ± 22.2 0.100
ALF (seconds)
8 meter walk time 9.4 ± 3.9 8.2 ± 2.1 0.172
Stand-sit-stand transfer
time
10.4 ± 5.3 8.4 ± 2.4 0.106
Stair ascent and
descent time
23.9 ± 15.1 16.5 ± 5.8 0.029*
ALF score 43.6 ± 23.2 33.1 ± 9.6 0.043*
SF-36 (0-100 scale)
SF-36 score results 54.1 ± 18.9 58.0 ± 17.2 0.446
Visual-analogue-scale for
pain
3.78 ± 3.04 4.60 ± 2.74 0.320
Knee Society Knee Score 60.04 ± 15.6 59.5 ± 17.1 0.911
Knee Society Function Score 60.4 ± 17.2 58.9 ± 13.1 0.734
Values are presented as mean ± SD.
* The significance threshold was set at p ≤ 0.05.
MSM = methylsulfonylmethane; WOMAC = Western Ontario and McMaster
Osteoarthritis Index; ALF = aggregated locomotor function; SF-36 = 36-item
short-form health survey.
There were significant differences between the groups at baseline in gender,
BMI and ALF score. Results of the study were adjusted to account for these
differences.
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while there was an increase of 12% (0.6 cm [CI: -0.6,
1 . 7 ] )o nt h eV A Si nt h ep l a c e b og r o u p .T h i sc o r r e -
sponded to a 0.7 cm [CI: -0.9, 2.4] difference between
the changes in each group (p = 0.05).
The secondary outcomes are presented in Table 3.
The KSKS showed a non-significant improvement of 9%
(5.4 [CI: -0.1, 10.9]) in the MSM group and a reduction
of 6% (3.6 [CI: -4.8, 12.1]) in the control group, corre-
sponding to a difference of 9.0 [CI: -0.8, 18.8] between
groups (p = 0.09). The KSKF showed a reduction in
function in both group. The MSM group showed a
decrease of 3% (2.0 [CI: -4.3, 8.3]) and the placebo
group showed a decrease of 4% (2.1 [CI: -3.0, 7.3]), cor-
responding to a difference of 0.1 [CI: -7.8, 8.1] between
groups (p = 0.63).
Discussion
T h ep r e s e ts t u d yf o u n dt h a tp a t i e n t sw i t hO Ao ft h e
knee treated with 3.375 g/d MSM for 12 weeks show a
significant improvement in the function and total score
scales of the WOMAC and in the VAS for pain com-
pared to a placebo-controlled group. Non-significant
improvements were found in the pain and stiffness
Table 2 Primary outcomes over the 12-week treatment period
MSM (n = 25) Placebo (n = 25) Significance for
between group
differences at
follow-ups
6 weeks 12
weeks
Difference 0-12 wk
[CI]
6 weeks 12
weeks
Difference 0-12 wk
[CI]
Between group
difference [CI]
0-6
wks
0-12
wks
WOMAC
Pain 35.5 ±
26.1
34.0 ±
24.5
-9.0 ± 24.0 [-18.9,
0.9]
47.1 ±
26.6
49.4 ±
20.8
3.5 ± 19.3 [-4.5,
11.5]
12.4 [0.0, 24.8] 0.20 0.05*
Stiffness 39.2 ±
31.0
36.0 ±
26.2
-11.7 ± 30.7 [-24.3,
1.0]
52.9 ±
30.4
58.5 ±
24.2
15.5 ± 35.8 [0.7,
30.3]
27.2 [8.2, 46.2] 0.03* 0.01*
Function 36.6 ±
23.7
33.1 ±
23.1
-7.7 ± 19.3 [-15.8,
0.3]
46.2 ±
25.1
54.3 ±
21.1
6.9 ± 17.0 [0.1, 13.9] 14.6 [4.3, 25.0] 0.51 0.01*
Total 36.6 ±
23.9
33.3 ±
22.5
-8.4 ± 17.8 [-15.8,
-1.1]
47.2 ±
24.5
53.5 ±
20.3
6.5 ± 17.0 [0.5, 13.5] 15.0 [5.1, 24.9] 0.26 0.00*
ALF 36.5 ±
16.6
36.9 ±
20.7
-6.8 ± 10.3 [-11.0,
-2.5]
32.2 ±
10.6
33.9 ±
10.9
0.8 ± 4.9 [-1.2, 2.8] 7.6 [2.9, 12.2] 0.02* 0.00*
SF-36 59.8 ±
19.7
62.2 ±
20.3
8.1 ± 21.8 [-0.8,
17.1]
61.1 ±
16.2
54.5 ±
15.4
-3.4 ± 14.6 [-9.5, 2.6] -11.6 [-22.1, -1.0] 0.52 0.03*
VAS 3.30 ±
2.8
3.61 ±
2.9
-0.2 ± 3.2 [-1.5, 1.1] 5.22 ±
2.9
5.16 ±
2.22
0.6 ± 2.7 [-0.6, 1.7] 0.7 [-0.9, 2.4] 0.18 0.38
Values are presented as mean ± SD.
* The significance threshold was set at p ≤ 0.05. Intention to treat analysis was carried out with the last observation carried-forward method.
CI = 95% confidence interval; MSM = methylsulfonylmethane; WOMAC = Western Ontario and McMaster Osteoarthritis Index graded from 0-100 mm, with 100
mm being the worst symptoms; ALF = Aggregated locomotor function in seconds; SF-36 = 36-item short-form health survey graded from 0-100, with 0 being the
worst pain and quality of life; VAS = Visual-analogue-scale graded from 0-10 cm for pain, with 10 cm being the worst pain.
Table 3 Adjusted primary and secondary outcomes over the 12-week treatment period
Significance for between group differences at follow-ups *
Outcome 0-6 wks 0-12 wks
Primary WOMAC
Pain 0.43 0.08
Stiffness 0.23 0.08
Function 0.85 0.04*
Total 0.60 0.03*
ALF 0.31 0.09
SF-36 0.98 0.54
VAS 0.06 0.05*
Secondary KSKS 0.43 0.09
KSFS 0.29 0.63
* The significance threshold was set at p ≤ 0.05.
WOMAC = Western Ontario and McMaster Osteoarthritis Index; ALF = Aggregated locomotor function; SF-36 = 36-item short-form health survey; VAS = Visual-
analogue-scale for pain; KSKS = Knee society knee score; KSFS = Knee society function score.
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KSKS.
The critical primary outcomes of the study were the
pain scale of the WOMAC and VAS for pain. Kim et al.
showed a 25.1% reduction in WOMAC pain in knee OA
patients treated with higher MSM doses than the pre-
sent study. A study by Usha showed a 33% reduction in
VAS for pain in knee OA patients treated with lower
MSM doses than the present study. Our results showed
a mean arthritic pain decrease of just 21.1% on the
WOMAC that had no significance and a decrease of
5.5% of the VAS pain scale that was significant. Neither
of these, nor the results of previous studies are consid-
ered to be clinical improvements according to the cri-
teria set forth by the OMERACT and OARSI. This falls
in agreement with the meta-analysis for DMSO/MSM
performed by Brien et al. that also showed a significant
but non-clinically significant improvement in WOMAC
or VAS scales for pain in the MSM group. Based on our
calculations there was an average decrease in pain of
39.5% across the studies used in the meta-analysis. As
reported by Brien et al., however, the average difference
between the changes found in each treatment group was
only 6.34 mm [17].
The other primary outcomes of the study were the other
WOMAC scales, SF-36 and ALF. The results of the other
WOMAC scales are in partial agreement with the study of
Kim et al. The present study found a significant improve-
ment in function and total score. Kim et al. found a signifi-
cant improvement in pain and physical function but not in
stiffness and aggregated total symptoms. Specifically,
MSM improved pain by 14.6 mm (p < 0.05), physical func-
tion by 15.7 mm (p < 0.05), stiffness by 10.1 mm (p =
0.320) and total WOMAC score by 13.4 mm (p = 0.054)
compared to the placebo [16].
The SF-36 results are also in agreement with the study
of Kim et al. In the present study the MSM group showed
a non-significant improvement of 15% in overall SF-36,
compared to a worsening of symptoms of 6% in the con-
trol group. This corresponded to a score difference of 11.6
between groups. The analysis carried out by Kim et al.
showed no significant differences between treatment
groups in almost all SF-36 scores. A significant difference
b e t w e e ng r o u p sw a so n l yf o u n di nt h ec a t e g o r yo fr o l e
limitation due to physical, with a mean change of 16.45
over 12 weeks (p = 0.021) [16].
The ALF and KSKS results showed similarities to the
outcomes of the study by Usha. Our ALF results showed a
non-significant 6.9-second improvement in physical func-
tion in the MSM group compared to the placebo group
and the KSKS showed a non-significant 9% improvement
in joint function corresponding to a 9.0-point difference
between the treatment groups. Similarly the study by Usha
found significant improvements in joint mobility, swelling,
global evaluation and walking time [15].
All but one study outcome (i.e. KSKF) showed a
greater improvement in knee OA symptoms in the
MSM compared to the control, yet many of these where
not significant at the end of the study. This may have
occurred for several reasons. First is that there were sig-
nificant baseline differences in gender, BMI and ALF
scores between the groups at baseline. Almost all out-
comes showed significance before adjusting for these
differences (Table 2). The reasons for the baseline differ-
ences may be due to our randomization technique. We
used unlabeled bottles of pills and randomized accord-
ing to the order in which patients arrived at the clinic.
A better randomization technique would have been to
use a randomization computer model. The small sample
size may also be a reason for the baseline differences.
The short time frame of the study may also have been
a difficulty. It is clear from Tables 2 and 3 that all out-
comes aside from KSFS continue to improve towards
significance at 12 weeks. There is a good chance that
had the study been continued for longer more of the
results would have been significant. Nevertheless, even
had many of the result been significant, it seems that
most of the improvement of symptoms seen in the
MSM group were minor and are likely not to have been
of clinical significance. Another fault of the study is the
use of a single enrollment site. This limited much of our
patient pool to a local area, and limits our ability to gen-
eralize the results on a larger scale. Future studies on
MSM should randomize the patient pool using compu-
terized models, lengthen the intervention period and
sample patients from different clinics and even different
countries.
With regard to safety analy s i s ,n oa d v e r s ee v e n t so r
side effects were recorded. In contrast, very minor side
effects were recorded in the study of Kim et al. These
included bloating, constipation, indigestion, fatigue,
inability to concentrate, insomnia and headaches. These
side effects, however, were observed in equal frequency
in the control group as well [16]. The lack of clinical
side effects in the present study was surprising. One rea-
son for the lack of adverse effects may be due to a dif-
ference in dosage. The dosage used by Kim et al. was
almost double the amount used in the present study.
Another possibility is the present study was not sensitive
enough at picking up these effects. It is possible that by
using more sensitive methods of evaluating side effects,
such as examining medical records, liver function tests
and implementing questionnaires, we would have found
slight side effects in our study population. Future studies
should examine the adverse effects of MSM more
thoroughly.
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efficacy of MSM is relatively smaller. For example, cele-
coxib and acetaminophen decreased the WOMAC pain
scale by 15.5 mm and 12.5 mm [31], respectively, while
MSM decreased WOMAC pain by just 9.1 mm and
VAS for pain by 1.7 mm in our study. The studies by
Usha and Kim et al. also showed just minor improve-
ments relative to NSAIDs [15,16]. A meta-analysis on
NSAIDs for knee OA showedt h e mt oh a v ea na v e r a g e
effect size of approximately0 . 3 2[ 3 2 ] .T h ee f f e c ts i z eo f
MSM in the present study (0.28) falls slightly below this
number. Compared to topical NSAIDs, which have been
shown to have an effect size of approximately 0.4 [33],
MSM also had a relatively smaller effect size in the pre-
sent study. On the other hand, MSM had a relatively
greater efficacy than intra-articular hyaluronic acid
injections, which have been shown to decrease pain by
only 4.3 mm [34]. These findings suggest that the effi-
cacy of MSM is modest in comparison to the standard
care for knee pain and falls below the efficacies of most
standard therapies. These comparisons, however, should
be interpreted with care considering that these studies
did not have identical methodologies.
On the other hand, the results of this study suggest
that long-term trials on MSM may yield additional and
greater improvements in knee OA symptoms. There are
also many serious risks associate with OA drugs, such
as those recently shown for COX-2 inhibitor drugs
[35,36]. MSM appears to be a relatively safe health sup-
plement. Current research suggests that if side effects to
MSM exist, they are minimal and include minor GI
symptoms, headaches, insomnia and difficulty concen-
trating [16]. With MSM’s lack of significant adverse
effects and with significant, albeit minor, improvements
in pain and function, patients with knee OA may benefit
from adding MSM to their treatment regiment. Such a
drug may be used in combination with current drugs
and therapies for arthritis pain and especially if other
drugs are contraindicated.
Conclusions
Patients with OA of the knee taking MSM for 12 weeks
showed an improvement in pain and physical function.
The results suggest that larger and long-term studies
may find additional and greater improvements in knee
OA symptoms. These improvements, however, are small
and it is yet to be determined if they are of clinical sig-
nificance. Further trials on MSM are recommended to
define the safety, efficacy and appropriate dosage of
MSM. We recommend incorporating longer interven-
tion periods, larger and wider patient populations, dose-
response trials and comparisons with other health sup-
plements and standard conventional treatments.
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